Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 11/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.45 |
| ▸ | FNTB | P49356 | 2/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7673651 | 0.83 | CACNA1H (0.45) | CACNA1HTRPA1EGLN2 | |
| SCHEMBL20141383 | 0.82 | TRPA1 (0.52) | CACNA1HTRPA1EGLN2 | |
| SCHEMBL7713236 | 0.81 | CYP11B1 (0.70) | CYP11B1CYP11B2CACNA1HFNTAFNTB | |
| SCHEMBL7168713 | 0.80 | FNTA (0.45) | CYP11B1CYP11B2CACNA1HFNTAFNTB | |
| SCHEMBL5880647 | 0.79 | CYP11B1 (0.61) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7713288 | 0.79 | CYP11B1 (0.54) | CYP11B1CYP11B2CACNA1H | |
| SCHEMBL7704743 | 0.79 | CYP11B1 (0.55) | CYP11B1CYP11B2CACNA1HFNTAFNTB | |
| SCHEMBL7971164 | 0.78 | CYP11B1 (0.52) | CYP11B1CYP11B2CACNA1H | |
| SCHEMBL7709344 | 0.78 | CYP11B1 (0.51) | CYP11B1CYP11B2CACNA1H | |
| Lithium Ion SCHEMBL7709340 | 0.77 | CYP11B2 (0.50) | CYP11B1CYP11B2CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6358985-B1 | ANTICANCER AGENT | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1091736-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6297239-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| EP-1091736-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001017992-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1021188-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000001382-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999017777-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | CYP11B1 530/4885CYP11B2 621/4885CACNA1H 4848/4885 |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | CYP11B1 3154/4885CYP11B2 3807/4885CACNA1H 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.